Table 1 Characteristics of studies investigating the effects of maintenance of BCG
First author, yr | Design, LOE | No. of Case/Control | Age Case/Control* | Disease category | Follow-up, mo Case/Control* | Strain | Treatment dose (mg) Maintenance/Induction |
|---|---|---|---|---|---|---|---|
Badalament 1987 [23] | RCT, 1b | 47/46 | 62.0/63.5 | Superficial BCa | 22(3–44) | Pasteur | 120/120 |
Koga 2010 [18] | RCT, 1b | 24/27 | NA | High-risk NMIBC | 26.5/28.7 | Tokyo | 80/80 |
Hinotsu 2011 [16] | RCT, 1b | 41/42 | NA | Recurrent or multiple NMIBC | 24 | Connaught | 80/40 |
Lamm 2000 [22] | RCT, 1b | 192/192 | 66.8/67.0 | Recurrent Ta, T1 and CIS | 119.1/120.3 | Connaught | 80/40 |
Palou 2001 [21] | RCT, 1b | 65/61 | 65.0/63.0 | CIS and/or high grade BCa | 77.8(7–120) | Connaught | 81/81 |
Hudson 1987 [24] | RCT, 1b | 21/21 | 60.0/62.0 | Superficial BCa | 16.1±1.4 | Pasteur | 120/120 |
Andius 2004 [20] | R, 2b | 52/80 | 74(31–96) | NMIBC without CIS | 44(4–155) | Danish/OncoTice | NA |
Okamura 2011 [17] | R, 2b | 48/27 | 64.0/68.0 | NMIBC without CIS | 102/66 | Tokyo 172 | 80/80 |
Decobert 2008 [19] | R, 2b | 31/40 | 64.3/69.5 | High-risk NMIBC | 31 | Pacis | 120/120 |